ANALYSIS OF MARKET DATA REGARDING THE MEDICINES USED
IN TREATMENT OF DYSLIPIDAEMIA
CORNELIA REVNIC1, REMUS CÂMPEAN1, ANAMARIA BOBOIA2*
"Iuliu Haţieganu” University of Medicine and Pharmacy Cluj-Napoca, Faculty of Pharmacy
1Mathematical and Computer Science Department, 6 Pasteur, 400349, Cluj-Napoca, Romania
2Pharmaceutical Management, Marketing and Legislation Department, 8 Victor Babeş, 400012, Cluj-Napoca, Romania
*corresponding author: aboboia@umfcluj.ro
Download Full Article

Abstract:
Dyslipidaemias are some of the most frequent metabolic diseases encountered in medical practice. Due to the increasing
number of patients suffering from dyslipidaemia, its treatment is frequently on medical prescriptions presented to
pharmacies. It was analysed a volume of 360 of patients and THEIR medical prescriptions provided by 12 pharmacies from
Cluj-Napoca during the year 2010. The drugs most frequently prescribed in the treatment of some forms of dyslipidaemia
have been the following: Simvastatin®10, Simvastatin®20, Simvastatin®40, Rosuvastatin®5, Rosuvastatin®10,
Rosuvastatin®20, Atorvastatin®10, Atorvastatin®20, Atorvastatin®40, Fenofibrat®160, Omacor®. All patients considered,
who has been administered one of these drugs, were chosen so that to respect the homogeneity on each age category, namely,
the age’s interval is quite symmetrically comparing to the average age. The aim of this paper was to find the most frequently
prescribed drug for dyslipidaemia. Also, the median differences between the younger and older groups were tested for
statistical significance using the Mann-Whitney test. In order to test the effect of medical treatment on 12 subgroups
corresponding to the period of time studied, namely, on 12 months, a Kruskal-Wallis nonparametric test was used.

Top